Pd07-09 a Prospective Paired Comparison Trial on Mirabegron and Anticholinergics in Patients With Low Bladder Compliance

You have accessJournal of UrologyUrodynamics/Lower Urinary Tract Dysfunction/Female Pelvic Medicine: Neurogenic Voiding Dysfunction (PD07)1 May 2024PD07-09 A PROSPECTIVE PAIRED COMPARISON TRIAL ON MIRABEGRON AND ANTICHOLINERGICS IN PATIENTS WITH LOW BLADDER COMPLIANCE Hee Seo Son and Jang Hwan Kim Hee Seo SonHee Seo Son and Jang Hwan KimJang Hwan Kim View All Author Informationhttps://doi.org/10.1097/01.JU.0001008552.16893.70.09AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: This study aimed to investigate the efficacy of a β3-adrenoceptor agonist (mirabegron) on bladder compliance (BC) in patients with low BC (≤ 20 ml/cmH2O), even with continuous treatment with anticholinergics. METHODS: This prospective single-arm paired comparison trial included patients enrolled in a tertiary referral center between January 2016 and October 2022. Patients with low BC of ≤20 ml/cmH2O in a urodynamic study performed while they were taking anticholinergics for more than one month were enrolled. After 2 weeks of the drug washout period, patients received mirabegron 50 mg/day for 8 weeks. Consecutive anticholinergics treatment (with the same regimen as that in the baseline assessment) was followed for 8 weeks. Urodynamic studies were performed at baseline, 8 weeks after mirabegron treatment and 8 weeks after anticholinergics treatment. Treatment effects were assessed by comparing urodynamic findings using paired t-tests. Data are expressed as mean and 95% confidence intervals, unless otherwise specified. RESULTS: Fourteen patients were enrolled male, 8; female, 6; age 54.4 (range 23.9∼78.3) years. As 3 patients refused to comply with the study after the completion of 8 weeks of mirabegron treatment, 11 patients completed the intended protocol. The duration of anticholinergics treatment at baseline assessment was 10.1 (range 2.1∼72.2) months. Baseline BC was 12.01 (9.52-14.52) ml/cmH2O. After 8 weeks of mirabegron treatment, BC increased significantly to 39.67 (21.60-57.73) ml/cmH2O (p=0.007). After returning to previously medicated anticholinergics for 8 weeks, BC decreased to 20.94 (15.78-26.10) ml/cmH2O, approaching conventional significance (p=0.075). Among the maximum cystometric capacity and detrusor pressure at end-filling, which comprise BC, the mirabegron effect was more conspicuous in decreasing the detrusor filling pressure, showing a significant change (p<0.001) compared to the increase in maximum cystometric capacity (p=0.091) (Table 1). CONCLUSIONS: Mirabegron showed a significant effect in improving low BC that could not be treated with anticholinergics. Improved BC was not maintained after returning to anticholinergics. β3-adrenoceptor agonist is considered superior to anticholinergics for improving BC. Source of Funding: The authors declare that no funding was provided for this study © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e170 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Hee Seo Son More articles by this author Jang Hwan Kim More articles by this author Expand All Advertisement PDF downloadLoading ...